FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Wyden Questions Pfizer Over Lyrica Price Hikes

Dec. 28, 2018
A A

Sen. Ron Wyden (D-Ore.), the ranking member of the Senate Finance Committee, is seeking an explanation for the steadily growing cost of Pfizer’s blockbuster drug Lyrica.

In a letter to Pfizer, the senator called out the drug company for routinely increasing the nerve pain treatment’s price over the past several years, noting that it “has grown tremendously” in that time period.

Wyden said the main cause of the increase in Medicare spending on the drug was “Pfizer’s consistent and egregious price increases.”

View today's stories